Time BioVentures Invests in DeepSight Technology's $25M Series A Round

Time BioVentures is thrilled to announce its investment in DeepSight™ Technology's $25 million Series A.

The round was led by Deerfield Management Company, with additional funding from Wing and Alter Venture Partners.

"We are excited to be on the frontier of advancing medical imaging," said founder and CEO Nader Sadrzadeh. "Based on internal studies, our technology has the potential to achieve 100 times greater sensitivity, ultimately allowing us to deliver better patient care."

DeepSight is augmenting diagnostic medical imaging with the introduction of novel ultrasound technology, using patented hardware, software, and AI algorithms to deliver 100 times higher sensitivity than other ultrasound systems in the market. Existing ultrasound technologies are limited by sensitivity, depth penetration, and clarity. DeepSight improves ultrasound image quality and more than doubles the effective range when compared to conventional technologies.

About DeepSight
Founded in 2019, DeepSight Technology's vision is to reinvent diagnostic imaging. DeepSight's proprietary sensor technology delivers a quantum leap in performance that vastly extends the range of diagnostic medical ultrasound to benefit public health and well-being. DeepSight is headquartered in the San Francisco Bay Area with offices in St. Louis, Missouri.

Original news release: https://www.prnewswire.com/news-releases/deepsight-technology-announces-25m-series-a-funding-round-301397143.html